Technical Analysis for KRTX - Karuna Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 104.52 9.17% 8.78
KRTX closed up 9.17 percent on Friday, January 17, 2020, on 1.13 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Up
Historical KRTX trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's lead product candidate is KarXT, an oral modulator that is in Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia, as well as in Phase Ib clinical trial for the treatment of central nervous system disorders, such as cognitive and negative symptoms, Alzheimer's, and pain. It also focuses on developing other muscarinic-targeted drug candidates. Karuna Pharmaceuticals, Inc. has a license agreement with Eli Lilly and Company; and patent license agreement with PureTech Health LLC. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts. Karuna Therapeutics, Inc. operates as a subsidiary of PureTech Health plc.
Biopharmaceutical Pain Schizophrenia Central Nervous System Disorders Alzheimer's Treatment Of Central Nervous System Disorders

Is KRTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 152.0
52 Week Low 11.24
Average Volume 972,284
200-Day Moving Average 0.00
50-Day Moving Average 67.67
20-Day Moving Average 77.88
10-Day Moving Average 80.15
Average True Range 8.15
ADX 49.53
+DI 41.66
-DI 6.84
Chandelier Exit (Long, 3 ATRs ) 80.97
Chandelier Exit (Short, 3 ATRs ) 89.50
Upper Bollinger Band 95.43
Lower Bollinger Band 60.32
Percent B (%b) 1.26
BandWidth 45.08
MACD Line 6.81
MACD Signal Line 4.50
MACD Histogram 2.3093
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 123.85
Resistance 3 (R3) 122.00 113.71 120.63
Resistance 2 (R2) 113.71 108.79 114.63 119.55
Resistance 1 (R1) 109.12 105.75 111.41 110.96 118.48
Pivot Point 100.82 100.82 101.97 101.75 100.82
Support 1 (S1) 96.23 95.90 98.53 98.08 90.56
Support 2 (S2) 87.94 92.86 88.86 89.49
Support 3 (S3) 83.34 87.94 88.41
Support 4 (S4) 85.19